ClinicalTrials.gov
public full text
Public Domain
Thymosin Alpha-1 for irAE Secondary to ICIs
Thymosin alpha-1 (Tα-1) has shown clinical benefits in patients whose immune functions are severely compromised or ineffective. Therefore, this study is attempted to explore whether Tα-1 could be used as a therapeutic option for the treatment of immune-related adverse events (irAEs).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients#377272
- Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer#162466
- Impact on T Cell Immune Activation and Inflammation of Triptolide Woldifii in HIV-infected Immunological Non-responders#1161769
- Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral Treatment#879047
- Human GPR174 deficiency drives polyclonal lymphoproliferative disease via defects in T cell function#456629
Record · ID 850611
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive